Omar Mian, MD, PhD
Associate Professor
Human Biology Division, Fred Hutch
Associate Professor, Precision Radiation Sciences Lead
Radiation Oncology Division, Fred Hutch
Dr. Omar Mian is a radiation oncologist focused on cancers of the genitourinary tract — primarily bladder, prostate and kidney cancers. As a physician-scientist, he studies the molecular features of these cancers in the lab. He investigates how genes and modifications to gene expression promote the progression of cancer from early-stage, curable forms to more aggressive and treatment-resistant ones with the goal of reversing that process, developing targeted therapies, and reducing therapeutic resistance.
His lab interprets leading-edge medical imaging techniques that track disease progression and studies patient tumor samples that have survived radiation therapy. The lab also uses cellular and animal model systems of human disease to study the fundamental biology and evolution of common and rare variant carcinomas. Dr. Mian also studies the role of nuclear hormone receptors in regulating DNA repair and resistance to chemotherapy and radiotherapy to identify the tell-tale biological signs of aggressive disease for which new therapies are needed.
Other Appointments & Affiliations
Associate Professor, Department of Radiation Oncology, University of Washington School of MedicineAssociate Professor, Department of Radiation Oncology
University of Washington School of Medicine
Education
MD (Radiation Oncology), Johns Hopkins University Baltimore, 2016
MD, PhD (PhD in the Department of Microbiology and Immunology), VCU School of Medicine, 2011
Research Interests
Molecular mechanisms underlying prostate and bladder cancer initiation, progression, and therapeutic resistance
Interplay between hormone receptor signaling and radiation resistance in prostate cancer
Mechanisms responsible for the transition from androgen-responsive prostate and bladder cancer to small-cell/neuroendocrine cancer
New and emerging radiotherapy delivery technologies, including targeted stereotactic ablative radiation, particle therapy (e.g., proton, neutron, radiopharmaceuticals), and dose rate modulation (e.g., FLASH)
Clinical Expertise
Prostate Cancer
Bladder Cancer
Testicular Cancer
Rare Genitourinary Cancers
“Discoveries in the research laboratory improve the lives of cancer patients and will one day end suffering and death from cancer. Each day, we have the opportunity to push the boundary of what’s possible in cancer care.”
— Dr. Omar Mian